130 related articles for article (PubMed ID: 21868575)
1. A novel inhibitor of focal adhesion signaling induces caspase-independent cell death in diffuse large B-cell lymphoma.
Bosch R; Dieguez-Gonzalez R; Céspedes MV; Parreño M; Pavón MÁ; Grañena A; Sierra J; Mangues R; Casanova I
Blood; 2011 Oct; 118(16):4411-20. PubMed ID: 21868575
[TBL] [Abstract][Full Text] [Related]
2. A celecoxib derivative inhibits focal adhesion signaling and induces caspase-8-dependent apoptosis in human acute myeloid leukemia cells.
Casanova I; Bosch R; Lasa A; Parreño M; Céspedes MV; Brunet S; Nomdedéu JF; Mangues MA; Sierra J; Mangues R
Int J Cancer; 2008 Jul; 123(1):217-26. PubMed ID: 18398841
[TBL] [Abstract][Full Text] [Related]
3. A novel orally available inhibitor of focal adhesion signaling increases survival in a xenograft model of diffuse large B-cell lymphoma with central nervous system involvement.
Bosch R; Moreno MJ; Dieguez-Gonzalez R; Céspedes MV; Gallardo A; Trias M; Grañena A; Sierra J; Casanova I; Mangues R
Haematologica; 2013 Aug; 98(8):1242-9. PubMed ID: 23716554
[TBL] [Abstract][Full Text] [Related]
4. Voruciclib, a clinical stage oral CDK9 inhibitor, represses MCL-1 and sensitizes high-risk Diffuse Large B-cell Lymphoma to BCL2 inhibition.
Dey J; Deckwerth TL; Kerwin WS; Casalini JR; Merrell AJ; Grenley MO; Burns C; Ditzler SH; Dixon CP; Beirne E; Gillespie KC; Kleinman EF; Klinghoffer RA
Sci Rep; 2017 Dec; 7(1):18007. PubMed ID: 29269870
[TBL] [Abstract][Full Text] [Related]
5. A Novel BCL-2 Inhibitor APG-2575 Exerts Synthetic Lethality With BTK or MDM2-p53 Inhibitor in Diffuse Large B-Cell Lymphoma.
Luo Q; Pan W; Zhou S; Wang G; Yi H; Zhang L; Yan X; Yuan L; Liu Z; Wang J; Chen H; Qiu M; Yang D; Sun J
Oncol Res; 2020 Sep; 28(4):331-344. PubMed ID: 32093809
[TBL] [Abstract][Full Text] [Related]
6. Heterogeneous Pattern of Dependence on Anti-Apoptotic BCL-2 Family Proteins upon CHOP Treatment in Diffuse Large B-Cell Lymphoma.
de Jong MRW; Langendonk M; Reitsma B; Nijland M; van den Berg A; Ammatuna E; Visser L; van Meerten T
Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31801186
[TBL] [Abstract][Full Text] [Related]
7. Celecoxib activates a novel mitochondrial apoptosis signaling pathway.
Jendrossek V; Handrick R; Belka C
FASEB J; 2003 Aug; 17(11):1547-9. PubMed ID: 12824303
[TBL] [Abstract][Full Text] [Related]
8. Cyclooxygenase-2 inhibitor celecoxib augments chemotherapeutic drug-induced apoptosis by enhancing activation of caspase-3 and -9 in prostate cancer cells.
Dandekar DS; Lopez M; Carey RI; Lokeshwar BL
Int J Cancer; 2005 Jun; 115(3):484-92. PubMed ID: 15688368
[TBL] [Abstract][Full Text] [Related]
9. Enhanced apoptotic effects by downregulating Mcl-1: evidence for the improvement of photodynamic therapy with Celecoxib.
Song J; Chen Q; Xing D
Exp Cell Res; 2013 Jun; 319(10):1491-504. PubMed ID: 23524145
[TBL] [Abstract][Full Text] [Related]
10. Death receptor regulation and celecoxib-induced apoptosis in human lung cancer cells.
Liu X; Yue P; Zhou Z; Khuri FR; Sun SY
J Natl Cancer Inst; 2004 Dec; 96(23):1769-80. PubMed ID: 15572759
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of SYK or BTK augments venetoclax sensitivity in SHP1-negative/BCL-2-positive diffuse large B-cell lymphoma.
Sasi BK; Martines C; Xerxa E; Porro F; Kalkan H; Fazio R; Turkalj S; Bojnik E; Pyrzynska B; Stachura J; Zerrouqi A; Bobrowicz M; Winiarska M; Priebe V; Bertoni F; Mansouri L; Rosenquist R; Efremov DG
Leukemia; 2019 Oct; 33(10):2416-2428. PubMed ID: 30872780
[TBL] [Abstract][Full Text] [Related]
12. Targeted inhibition of PI3Kα/δ is synergistic with BCL-2 blockade in genetically defined subtypes of DLBCL.
Bojarczuk K; Wienand K; Ryan JA; Chen L; Villalobos-Ortiz M; Mandato E; Stachura J; Letai A; Lawton LN; Chapuy B; Shipp MA
Blood; 2019 Jan; 133(1):70-80. PubMed ID: 30322870
[TBL] [Abstract][Full Text] [Related]
13. Homoharringtonine interacts synergistically with bortezomib in NHL cells through MCL-1 and NOXA-dependent mechanisms.
Nguyen T; Parker R; Zhang Y; Hawkins E; Kmieciak M; Craun W; Grant S
BMC Cancer; 2018 Nov; 18(1):1129. PubMed ID: 30445933
[TBL] [Abstract][Full Text] [Related]
14. Celecoxib induces anoikis in human colon carcinoma cells associated with the deregulation of focal adhesions and nuclear translocation of p130Cas.
Casanova I; Parreño M; Farré L; Guerrero S; Céspedes MV; Pavon MA; Sancho FJ; Marcuello E; Trias M; Mangues R
Int J Cancer; 2006 May; 118(10):2381-9. PubMed ID: 16353145
[TBL] [Abstract][Full Text] [Related]
15. A novel celecoxib derivative, OSU03012, induces cytotoxicity in primary CLL cells and transformed B-cell lymphoma cell line via a caspase- and Bcl-2-independent mechanism.
Johnson AJ; Smith LL; Zhu J; Heerema NA; Jefferson S; Mone A; Grever M; Chen CS; Byrd JC
Blood; 2005 Mar; 105(6):2504-9. PubMed ID: 15454489
[TBL] [Abstract][Full Text] [Related]
16. Synergistic induction of apoptosis in high-risk DLBCL by BCL2 inhibition with ABT-199 combined with pharmacologic loss of MCL1.
Li L; Pongtornpipat P; Tiutan T; Kendrick SL; Park S; Persky DO; Rimsza LM; Puvvada SD; Schatz JH
Leukemia; 2015 Aug; 29(8):1702-12. PubMed ID: 25882699
[TBL] [Abstract][Full Text] [Related]
17. Celecoxib derivatives induce apoptosis via the disruption of mitochondrial membrane potential and activation of caspase 9.
Ding H; Han C; Zhu J; Chen CS; D'Ambrosio SM
Int J Cancer; 2005 Feb; 113(5):803-10. PubMed ID: 15499625
[TBL] [Abstract][Full Text] [Related]
18. Interferon-α and cyclooxygenase-2 inhibitor cooperatively mediates TRAIL-induced apoptosis in hepatocellular carcinoma.
Zuo C; Qiu X; Liu N; Yang D; Xia M; Liu J; Wang X; Zhu H; Xie H; Dan H; Li Q; Wu Q; Burns M; Liu C
Exp Cell Res; 2015 May; 333(2):316-326. PubMed ID: 25724899
[TBL] [Abstract][Full Text] [Related]
19. Combined cetuximab and celecoxib treatment exhibits a synergistic anticancer effect on human oral squamous cell carcinoma in vitro and in vivo.
Qian M; Qian D; Jing H; Li Y; Ma C; Zhou Y
Oncol Rep; 2014 Oct; 32(4):1681-8. PubMed ID: 25328959
[TBL] [Abstract][Full Text] [Related]
20. Strategic Therapeutic Targeting to Overcome Venetoclax Resistance in Aggressive B-cell Lymphomas.
Pham LV; Huang S; Zhang H; Zhang J; Bell T; Zhou S; Pogue E; Ding Z; Lam L; Westin J; Davis RE; Young KH; Medeiros LJ; Ford RJ; Nomie K; Zhang L; Wang M
Clin Cancer Res; 2018 Aug; 24(16):3967-3980. PubMed ID: 29666304
[No Abstract] [Full Text] [Related]
[Next] [New Search]